(Q51053343)

English

A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice.

scientific article published in March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

eradication of infectious diseases

1 reference

based on heuristic

inferred from title

author name string

Xinxin Song

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Wenzhong Guo

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Jianfeng Cui

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Xinlai Qian

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Linan Yi

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Mengjiao Chang

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Qiliang Cai

7

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Qingzheng Zhao

8

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

language of work or name

0 references

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

128

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

1129-1138

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Recent advances in cancer vaccines: an overview

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

The tumor microenvironment and its role in promoting tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Chemotherapy and tumor immunity: an unexpected collaboration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Targeted therapies to improve tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Myeloid suppressor cells regulate the adaptive immune response to cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Immunosuppressive strategies that are mediated by tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

The STATs of cancer--new molecular targets come of age

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Suppressors of cytokine signaling and immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

In vitro and in vivo growth inhibition of SC-M1 gastric cancer cells by retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25451

21 January 2018

Identifiers

10.1002/IJC.25451

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20473939

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51053343&oldid=1237367286"